ArticleCureus2026
Expanding the Clinical Spectrum of Bardet-Biedl Syndrome: Chronic Liver Disease in an Adult Patient.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy with multisystem involvement, classically characterized by retinal dystrophy, obesity, postaxial polydactyly, and renal abnormalities. We report a 30-year-old patient who presented with progressive visual impairment, truncal obesity, and postaxial polydactyly. Comprehensive evaluation revealed clinical, biochemical, and radiological features consistent with chronic liver disease, with common etiologies - including viral hepatitis, alcohol-related liver disease, and autoimmune disorders - excluded. Recognition of the constellation of systemic features led to the diagnosis of BBS in adulthood, highlighting a significant delay in syndromic identification. This case emphasizes chronic liver disease as a potentially underrecognized manifestation of BBS and illustrates the impact of delayed diagnosis on disease burden. Early recognition of BBS and systematic multisystem screening, including hepatic evaluation, is essential to enable timely intervention and improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.